Targeting the Transforming Growth FactorB Signaling Pathway in Human Cancer
The TGF-β signaling pathway offers many different avenues for therapeutic intervention, each of which offers advantages and drawbacks. Current therapeutic approaches for modulating TGF-β signaling involve antagonism of TGF-β ligand binding to the heteromeric receptor complex with isoform-selective antibodies as large molecule inhibitors, such as metelimumab (for TGF-β2) and lerdelimumab (for TGF-β2/3) from Genzyme, and pan-TGF-β antibodies such as GC-1008 (Genzyme), ID-11 (Genzyme), SR-2F (NCI/NIH) and 2G7 (Genentech) antibodies, or soluble TGFβRII receptor fusion proteins (Biogen). Alternatively, the intracellular inhibition of the TGFβRI kinase can be achieved with small molecule inhibitors, such as SB431542 and SB505124 from GlaxoSmithKline; LY580276, LY550410, LY364947, LY573636 and LY2157299 from Eli Lilly; SD093 and SD208 from Scios. Other inhibitors for TGF-β receptor kinase are NPC30345 (Scios), Ki-26894 (Kirin brewery), SM16, A-83-01 (Kyoto Pharma), SX-007 (Scios) and IN-1130 (In2Gen), and dual inhibitors of both the TGFβRI and TGFβRII kinases, such as LY2109761 (Eli Lilly). Alternatively, expression of TGF-β isoforms can be affected by antisense technology targeting mRNA sequence-specific degradation, such as AP-12009 and AP-11014 which were developed by Antisense Pharma and targeted to TGFβII and TGFβI, respectively. SIS3 is a selective chemical inhibitor of Smad3 activation and Smad3-mediated DNA binding and gene expression.